SI3498734T1 - Kombinacija antagonista PD-1 in zaviralca VEGFR za zdravljenje raka - Google Patents

Kombinacija antagonista PD-1 in zaviralca VEGFR za zdravljenje raka

Info

Publication number
SI3498734T1
SI3498734T1 SI201531757T SI201531757T SI3498734T1 SI 3498734 T1 SI3498734 T1 SI 3498734T1 SI 201531757 T SI201531757 T SI 201531757T SI 201531757 T SI201531757 T SI 201531757T SI 3498734 T1 SI3498734 T1 SI 3498734T1
Authority
SI
Slovenia
Prior art keywords
antagonist
combination
treating cancer
vegfr inhibitor
vegfr
Prior art date
Application number
SI201531757T
Other languages
English (en)
Slovenian (sl)
Inventor
Jean-Francais Andre Martini
Jamal Christo Tarazi
Rodolfo Fleury Perini
David J. Mauro
Original Assignee
Pfizer Inc.
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52463238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3498734(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc., Merck Sharp & Dohme Corp. filed Critical Pfizer Inc.
Publication of SI3498734T1 publication Critical patent/SI3498734T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI201531757T 2014-02-04 2015-02-03 Kombinacija antagonista PD-1 in zaviralca VEGFR za zdravljenje raka SI3498734T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461935809P 2014-02-04 2014-02-04
EP18205542.6A EP3498734B1 (en) 2014-02-04 2015-02-03 Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer

Publications (1)

Publication Number Publication Date
SI3498734T1 true SI3498734T1 (sl) 2022-02-28

Family

ID=52463238

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201531757T SI3498734T1 (sl) 2014-02-04 2015-02-03 Kombinacija antagonista PD-1 in zaviralca VEGFR za zdravljenje raka
SI201530602T SI3102605T1 (sl) 2014-02-04 2015-02-03 Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201530602T SI3102605T1 (sl) 2014-02-04 2015-02-03 Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka

Country Status (22)

Country Link
US (3) US10570202B2 (enExample)
EP (3) EP3102605B1 (enExample)
JP (3) JP6591428B2 (enExample)
KR (3) KR20160108566A (enExample)
CN (2) CN118286440A (enExample)
AU (1) AU2015214390B2 (enExample)
BR (1) BR112016017256A2 (enExample)
CA (2) CA2937521C (enExample)
CY (2) CY1121374T1 (enExample)
DK (1) DK3102605T3 (enExample)
EA (1) EA201691376A1 (enExample)
ES (2) ES2710211T3 (enExample)
HU (2) HUE041469T2 (enExample)
IL (2) IL311399A (enExample)
MX (1) MX386604B (enExample)
PL (2) PL3498734T3 (enExample)
PT (2) PT3498734T (enExample)
SG (2) SG11201605824XA (enExample)
SI (2) SI3498734T1 (enExample)
TR (1) TR201901507T4 (enExample)
TW (1) TWI663983B (enExample)
WO (1) WO2015119930A1 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
EP3079699A4 (en) * 2013-12-11 2017-07-19 Glaxosmithkline LLC Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
TW201613635A (en) 2014-02-04 2016-04-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
CN118286440A (zh) * 2014-02-04 2024-07-05 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
WO2015134605A1 (en) * 2014-03-05 2015-09-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
IL278423B2 (en) 2015-02-26 2024-04-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
US11326211B2 (en) 2015-04-17 2022-05-10 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to PD-1 antagonists
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
CN105669864B (zh) * 2015-12-23 2018-10-16 杭州尚健生物技术有限公司 抗人程序性死亡受体1抗体及其制备方法和用途
CN107126563B (zh) * 2016-02-26 2021-09-10 博生吉医药科技(苏州)有限公司 含低剂量阻断vegf信号通路的抗体的组合物及其用途
KR20190017767A (ko) * 2016-06-10 2019-02-20 노파르티스 아게 C-raf 억제제의 치료적 용도
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
WO2018044888A1 (en) * 2016-08-29 2018-03-08 Chen James C Tumor vaccination systems, devices, and methods
CN110036030A (zh) * 2016-09-26 2019-07-19 英克隆有限责任公司 癌症的组合疗法
EP3515495A4 (en) * 2016-09-26 2020-08-26 Ensemble Group Holdings CANCER ASSESSMENT AND TREATMENT PROCEDURES IN SUBJECTS WITH DYSREGULATED LYMPHATIC SYSTEMS
CA3039451A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
TWI764943B (zh) 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
WO2018133837A1 (en) 2017-01-20 2018-07-26 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-1 antibodies and uses thereof
PL3589754T3 (pl) 2017-03-01 2023-10-09 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
CA3055402A1 (en) * 2017-03-06 2018-09-13 Merck Patent Gmbh Aqueous anti-pd-l1 antibody formulation
WO2018183408A1 (en) * 2017-03-31 2018-10-04 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody
WO2018208968A1 (en) 2017-05-09 2018-11-15 Tesaro, Inc. Combination therapies for treating cancer
CN106963948A (zh) * 2017-05-12 2017-07-21 顾艳宏 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用
WO2018210230A1 (zh) 2017-05-16 2018-11-22 江苏恒瑞医药股份有限公司 一种pd-l1抗体药物组合物及其用途
DK3630112T3 (da) 2017-06-02 2024-04-22 Bayer Healthcare Llc Kombination af regorafenib og nivolumab til behandling af cancer
CN111328286B (zh) * 2017-08-09 2024-08-23 奥里尼斯生物科学有限公司 Pd-1和pd-l1结合剂
KR102760684B1 (ko) * 2017-09-29 2025-01-24 브리스톨-마이어스 스큅 컴퍼니 암을 치료하기 위한 조성물 및 방법
BR112020006371A2 (pt) * 2017-10-13 2020-09-29 Merck Patent Gmbh combinação de um inibidor de parp e um antagonista de ligação de eixo de pd-1
PL3707510T3 (pl) 2017-11-06 2024-09-30 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
CN111065411B (zh) * 2017-11-16 2023-03-10 江苏恒瑞医药股份有限公司 Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
TW201938165A (zh) * 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
JP2021527714A (ja) * 2018-06-20 2021-10-14 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ 抗ｐｄ−１抗体及びその使用
TWI890148B (zh) 2018-06-23 2025-07-11 美商建南德克公司 以pd-1軸結合拮抗劑、鉑劑及拓撲異構酶ii抑制劑治療肺癌之方法
CN112839644A (zh) 2018-07-18 2021-05-25 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、抗代谢物和铂剂治疗肺癌的方法
CN112424231B (zh) * 2018-07-19 2022-09-13 大有华夏生物医药集团有限公司 抗pd-1抗体及其剂量和用途
JP7535500B2 (ja) 2018-09-03 2024-08-16 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｔｅａｄモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体
EP3867646A1 (en) * 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for sarcomatoid kidney cancer
US20210388090A1 (en) * 2018-10-31 2021-12-16 Genentech, Inc. Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor
MX2021005189A (es) * 2018-11-05 2022-01-18 Aveo Pharmaceuticals Inc Uso de tivozanib para tratar sujetos con cancer refractario.
TWI822897B (zh) * 2018-11-06 2023-11-21 大陸商江蘇恆瑞醫藥股份有限公司 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途
TW202515617A (zh) 2019-01-14 2025-04-16 美商建南德克公司 用於癌症療法之rna分子
CA3134522A1 (en) 2019-04-19 2020-10-22 Genentech, Inc. Anti-mertk antibodies and their methods of use
MX2022005775A (es) 2019-11-13 2022-06-09 Genentech Inc Compuestos terapeuticos y metodos de uso.
MX2022009391A (es) 2020-01-31 2022-09-26 Genentech Inc Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn.
WO2021195163A1 (en) 2020-03-25 2021-09-30 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
WO2022004760A1 (ja) 2020-06-30 2022-01-06 塩野義製薬株式会社 抗ｃｃｒ８抗体と化学療法剤の併用
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
WO2022052874A1 (zh) 2020-09-09 2022-03-17 深圳微芯生物科技股份有限公司 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
TW202233671A (zh) 2020-10-20 2022-09-01 美商建南德克公司 Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
KR20230095113A (ko) 2020-11-04 2023-06-28 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
MX2023006488A (es) 2020-12-02 2023-06-20 Genentech Inc Procedimientos y composiciones para el tratamiento neoadyuvante y adyuvante del carcinoma urotelial.
JP2024516230A (ja) 2021-04-30 2024-04-12 ジェネンテック， インコーポレイテッド がんのための治療及び診断方法並びに組成物
KR20240005691A (ko) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
CN115400115B (zh) * 2021-05-26 2025-01-14 石药集团中奇制药技术（石家庄）有限公司 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途
KR20240028452A (ko) 2021-07-02 2024-03-05 제넨테크, 인크. 암을 치료하기 위한 방법 및 조성물
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
KR20240038008A (ko) 2021-07-28 2024-03-22 에프. 호프만-라 로슈 아게 암 치료 방법 및 조성물
EP4378460A4 (en) * 2021-07-28 2025-08-06 Tiumbio Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF A TUMOR AND CORRESPONDING USE
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
EP4436969A2 (en) 2021-11-24 2024-10-02 Genentech, Inc. Bicyclic therapeutic compounds and methods of use in the treatment of cancer
US12110276B2 (en) 2021-11-24 2024-10-08 Genentech, Inc. Pyrazolo compounds and methods of use thereof
WO2023134787A2 (zh) * 2022-01-14 2023-07-20 上海君实生物医药科技股份有限公司 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途
CN119136822A (zh) * 2022-03-04 2024-12-13 帕诺洛斯生物科技有限公司 包括VEGF-Grab和PD-1或PD-L1拮抗剂的联合治疗组合物
AU2022450448A1 (en) 2022-04-01 2024-10-10 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4522653A1 (en) 2022-05-11 2025-03-19 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
CA3261147A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
JP2025523845A (ja) 2022-07-19 2025-07-25 ジェネンテック， インコーポレイテッド 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬
JP2025531738A (ja) 2022-09-01 2025-09-25 ジェネンテック， インコーポレイテッド 膀胱がんの治療方法及び診断方法
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
EP4599089A1 (en) 2022-10-05 2025-08-13 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024091991A1 (en) 2022-10-25 2024-05-02 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
WO2024137589A2 (en) 2022-12-20 2024-06-27 Genentech, Inc. Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
EP4583930A1 (en) 2023-04-11 2025-07-16 Ocular Therapeutix, Inc. Ocular implant comprising axitinib polymorph iv
WO2024218649A2 (en) * 2023-04-17 2024-10-24 Aurigene Oncology Limited Combination of a protein kinase inhibitor with immunomodulatory agents
TW202448949A (zh) 2023-05-05 2024-12-16 美商建南德克公司 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
AU2024268933A1 (en) 2023-05-10 2025-11-20 Chugai Seiyaku Kabushiki Kaisha Methods and compositions for treating cancer
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
TW202502813A (zh) * 2023-06-30 2025-01-16 美商默沙東有限責任公司 包含偶聯物的藥物組合的治療方法和用途
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
TW202515614A (zh) 2023-08-25 2025-04-16 美商建南德克公司 治療非小細胞肺癌之方法及組成物
WO2025085404A1 (en) 2023-10-16 2025-04-24 Genentech, Inc. Diagnostic and therapeutic methods for treating lung cancer
TW202539700A (zh) 2024-01-16 2025-10-16 美商建南德克公司 用ｐｄ－１軸結合拮抗劑及ｒｎａ疫苗治療泌尿上皮癌之方法
WO2025174933A1 (en) 2024-02-14 2025-08-21 Genentech, Inc. Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CN1214043C (zh) 1998-12-01 2005-08-10 蛋白质设计实验室股份有限公司 抗γ－干扰素的人化抗体
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
US6778740B2 (en) * 2002-07-31 2004-08-17 Agilent Technologies, Inc. Alignment of optical fiber elements
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
RU2341263C2 (ru) * 2003-04-03 2008-12-20 Пфайзер Инк. Лекарственные формы, содержащие ag013736
RU2007114112A (ru) 2004-11-02 2008-12-10 Пфайзер Инк. (US) Способ получения индазольных соединений
CN101052633A (zh) 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
WO2006048746A2 (en) 2004-11-02 2006-05-11 Pfizer Inc. Methods for the removal of heavy metals
AU2005300317A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole
KR20070058690A (ko) 2004-11-02 2007-06-08 화이자 인코포레이티드 인다졸 화합물의 제조방법
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
US20080274192A1 (en) 2005-05-19 2008-11-06 Pfizer Inc. Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor
HRP20080053A2 (hr) 2005-07-01 2009-08-31 Medarex Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
WO2008100562A2 (en) * 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
MX2009010761A (es) 2007-04-05 2009-10-28 Pfizer Prod Inc Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos.
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2662383A1 (en) 2008-08-25 2013-11-13 Amplimmune, Inc. PD-I antagonists and methods for treating infectious disease
EP3133086B1 (en) 2008-09-26 2018-08-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
CA3120172A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
EP2691112B1 (en) * 2011-03-31 2018-05-23 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
MX2014003886A (es) 2011-09-30 2014-05-13 Pfizer Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida.
WO2013068909A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
KR20200075023A (ko) * 2012-05-04 2020-06-25 화이자 인코포레이티드 전립선 관련된 항원 및 백신 기재 면역치료 요법
SG10201603055WA (en) 2012-05-31 2016-05-30 Genentech Inc Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014163684A1 (en) 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
KR20210063475A (ko) 2013-11-07 2021-06-01 데시페라 파마슈티칼스, 엘엘씨. 암치료에 유용한 tie2 키나아제의 억제 방법
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
FI3083686T4 (fi) 2013-12-17 2023-05-09 Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN118286440A (zh) 2014-02-04 2024-07-05 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
CA2942039A1 (en) 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
WO2015134605A1 (en) 2014-03-05 2015-09-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US9603850B2 (en) 2014-04-11 2017-03-28 The University Of North Carolina At Chapel Hill MerTK-specific pyrazolopyrimidine compounds
CA2949121A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk
EP3200775B1 (en) 2014-10-03 2019-11-20 Novartis AG Combination therapies
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
PL3212670T3 (pl) 2014-10-29 2021-06-14 Five Prime Therapeutics, Inc. Leczenie skojarzone nowotworów
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法

Also Published As

Publication number Publication date
JP6591428B2 (ja) 2019-10-16
HUE057205T2 (hu) 2022-04-28
AU2015214390B2 (en) 2020-05-07
AU2015214390A1 (en) 2016-08-04
ES2899457T3 (es) 2022-03-11
EA201691376A1 (ru) 2017-01-30
IL311399A (en) 2024-05-01
EP3102605B1 (en) 2018-11-14
CA2937521C (en) 2023-08-29
CY1124785T1 (el) 2022-11-25
CA3210360A1 (en) 2015-08-13
TR201901507T4 (tr) 2019-02-21
BR112016017256A2 (pt) 2017-10-17
TW201615212A (zh) 2016-05-01
CA2937521A1 (en) 2015-08-13
KR20250109796A (ko) 2025-07-17
IL246760A0 (en) 2016-08-31
JP6894952B2 (ja) 2021-06-30
PT3498734T (pt) 2021-12-06
WO2015119930A1 (en) 2015-08-13
HUE041469T2 (hu) 2019-05-28
MX2016010082A (es) 2016-10-07
US20200325228A1 (en) 2020-10-15
EP3971209A1 (en) 2022-03-23
CN105960415A (zh) 2016-09-21
US10570202B2 (en) 2020-02-25
TWI663983B (zh) 2019-07-01
EP3498734B1 (en) 2021-09-01
MX386604B (es) 2025-03-19
PL3498734T3 (pl) 2022-02-14
JP2021130709A (ja) 2021-09-09
NZ722296A (en) 2023-09-29
EP3498734A1 (en) 2019-06-19
SG11201605824XA (en) 2016-08-30
US20170166641A1 (en) 2017-06-15
EP3102605A1 (en) 2016-12-14
KR20160108566A (ko) 2016-09-19
CN118286440A (zh) 2024-07-05
JP2020007359A (ja) 2020-01-16
ES2710211T3 (es) 2019-04-23
US20220324979A1 (en) 2022-10-13
DK3102605T3 (en) 2019-02-25
CY1121374T1 (el) 2020-05-29
SI3102605T1 (sl) 2019-04-30
PT3102605T (pt) 2019-02-12
JP2017506227A (ja) 2017-03-02
SG10201806656UA (en) 2018-09-27
KR20230023810A (ko) 2023-02-17
PL3102605T3 (pl) 2019-06-28

Similar Documents

Publication Publication Date Title
IL246760A0 (en) Combination of pd-1 antagonist and vegfr inhibitor for cancer treatment
IL247102B1 (en) Combination of pd-1 antagonist and ido1 inhibitor for cancer treatment
IL276314A (en) Preparations for the treatment of cancer using PD-1 axis binding antagonists and MEK inhibitors
IL250187B (en) A combination of a pd-1 antagonist and a listeria-based vaccine for the treatment of prostate cancer
IL254133B (en) Combination of pd-1 antagonist and eribulin for cancer treatment
IL263178A (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
IL254131A0 (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
IL252610A0 (en) Methods and preparations for the treatment of cancer
IL249658A0 (en) Methods of treating cancer using tigit inhibitors and anticancer agents
EP3079699A4 (en) Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
ZA201608560B (en) Method for treating cancer using a combination of chk1 and atr inhibitors
WO2016154412A9 (en) Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer
PL3164394T3 (pl) Inhibitory GLS1 do leczenia chorób
IL265917A (en) Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
PL3364971T3 (pl) Heterocykliczne inhibitory PDK1 do zastosowania w leczeniu nowotworu